For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.
Read More
Unlocking T1D Risk: Environmental and Genetic Factors Investigated
February 22nd 2024Outside of genetics, which has a well-documented link to the risk of type 1 diabetes (T1D), investigators detail available research spanning a variety of factors, including viral infections, pesticide exposure, and the gut microbiome.
Read More
Venetoclax Plus HMA Therapy Shows Encouraging Results in Higher-Risk MDS/CMML
February 22nd 2024Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of venetoclax and decitabine plus cedazuridine.
Read More
Patients With Early vs Advanced HCC Show Distinct Gut Microbiota Alterations
February 21st 2024Patients with early-stage hepatocellular carcinoma (HCC) and those with advanced-stage disease exhibited distinct gut microbiota diversity and alterations, with future studies warranted to investigate the mechanisms underlying the interactions between gut microbiota and HCC progression.
Read More
The amount of in-network care claims jumped significantly after surprise billing protections took effect; experts say the US is in the midst of the “fourth wave” of the opioid epidemic; the prevalence of long COVID symptoms 30 and 90 days post infection was 43% to 58% lower among adults who were fully vaccinated before infection.
Read More
Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL
February 20th 2024A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).
Read More
What We’re Reading: Weight Loss Drug Coverage; COVID Vaccine Potential AEs; Shifting Medicaid Policy
February 20th 2024Insurers grapple with expanding overage for weight loss medications; a new analysis reveals a potential correlation between COVID-19 vaccinations and various adverse effects (AEs); reshaping Medicaid programs remains an ongoing debate about ensuring health care access.
Read More
Access to Cancer Care Alleviates Racial Disparities in CLL/SLL
February 19th 2024No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and received cancer care or had access to a hematologist/oncologist.
Read More
Carrie Kozlowski on Access, AI, and the Future of Health Care Data Utilization
February 19th 2024Carrie Kozlowski, OT, MBA highlights 3 key trends shaping the future of health care: a focus on health equity with actionable strategies for equitable access to care, a transition toward responsible AI utilization, and a push to maximize the potential of patient data while addressing privacy concerns.
Watch
FDA Accepts BLA for Datopotamab Deruxtecan for Nonsquamous NSCLC
February 19th 2024The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress.
Read More
Dr Jun Gong: Improved Access Closes the Gaps Between Black, White Men With Prostate Cancer
February 18th 2024Despite socioeconomic and biological differences that contribute to disparities between Black men and White men with prostate cancer, improved access has been shown to reduce the gaps, explained Jun Gong, MD, of Cedars Sinai.
Read More